# Varegacestat

Source: https://onco.cc/drugs/varegacestat/  
OnCo record `varegacestat` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Varegacestat is an experimental small-molecule drug from Immunome in phase 3 trials for desmoid tumour, with its target not yet stated publicly.

## Summary

Varegacestat (AL102) is a small-molecule drug developed by Immunome. The sponsor describes its target as gamma secretase / Notch signalling, which OnCo does not yet have a target page for. The sponsor states: AL102 (varegacestat) is a small-molecule inhibitor of gamma secretase-mediated Notch signalling. ClinicalTrials.gov describes the intervention as: AL102 is an inhibitor of gamma secretase-mediated Notch signaling. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT04871282 (A Study of AL102 in Patients With Progressing Desmoid Tumours), in desmoid tumour. The largest, NCT04871282, plans to enrol 198 participants (actual) with primary completion was scheduled for 2025-12-03 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Code: AL102
- Modality: small molecule
- Mechanism: AL102 (varegacestat) is a small-molecule inhibitor of gamma secretase-mediated Notch signalling.

## Sources

- ClinicalTrials.gov: trials of Varegacestat: https://clinicaltrials.gov/search?intr=Varegacestat

## Connected records

- cancers: [Desmoid tumour](https://onco.cc/cancers/desmoid-tumour/)
- companies: [Immunome](https://onco.cc/companies/immunome/)
- trials: [A Study of AL102 in Patients With Progressing Desmoid Tumors](https://onco.cc/trials/nct04871282/)

---
JSON: https://onco.cc/api/v1/entities/varegacestat.json